Home | Reports | Startups | Press Releases | Blog | Online Store | site map


Developments

Financings

Reports

Startups
blog
Blog
Medtech podcast
Podcast

Cardiology

Surgery

Methodology

Order Report

Technologies, Products and U.S. Markets in Peripheral Stents

225 pages   49 Exhibits   14 Company Profiles   Published July 2003   Report #C275

This report is a detailed market and technology assessment and forecast of the products and technologies involved in the area of peripheral vascular and non-vascular stents. The report assesses the U.S. market size and competitor shares for companies with products on the market.  The report details the current progress of technologies, product and market development, with a ten-year forecast of the evolution of the market describing the expected timeline and market impact of emerging technologies. The analysis is focused on identifying windows of opportunity for current or hopeful competitors.

 

TABLE OF CONTENTS

 

Executive Summary

i. U.S. Peripheral Vascular and Non-Vascular Stent Marketplace

ii. Peripheral Vascular and Neurovascular Stent Systems

iii. Non-Vascular Stent Systems

Section 1:   Stenting Devices Technical & Clinical Overview

1.1   Stent in the Management of Vascular and Non-Vascular Circulatory Obstructions

1.2   Stent Architecture, Materials, Deployment Mechanisms

1.3   Emerging Stent Technologies

1.3.1    Drug Eluting Stents

1.3.1.1     Anti-Restenosis Agents and Delivery Mechanisms

1.3.1.2     Peripheral and Neurovascular Drug-Eluting Stents Under Development

1.3.1.3     Standard Metal Stenting With Adjuvant Orally-Administered Drug Therapy

1.3.2    Biodegradable Stents

1.4   Competing Revascularization Technologies

1.4.1    Cryoplasty

1.4.2    Excimer Laser Angioplasty

1.4.2.1     Peripheral Excimer Laser Angioplasty

1.4.3    Angiogenesis

1.4.3.1     Angiogenic Gene Therapy

1.4.3.1.1      Aventis Gencell

1.4.3.1.2      Corautus Genetics

1.4.3.1.3      GenVec

1.4.3.1.4      Schering AG

1.4.3.1.5      Valentis

1.4.3.2     Angiogenic Stem Cell Therapy

Section 2:     Peripheral Vascular Stenting Products

2.1   Abdominal Aortic Aneurysm Repair

2.1.1    Standard Therapies for Unstable Aortic Aneurysms

2.1.2    Endovascular Repair of Abdominal Aortic Aneurysm

2.1.3    AAA Endografts on the Market and Under Development

2.1.3.1     Clinical Experience with AAA Endografts

2.1.4    U.S. Market for AAA Endografts

2.1.4.1     Competitive Analysis

2.2   Carotid Artery Stents in Stroke Prevention

2.2.1    Ischemic Stroke and Carotid Artery Stenosis

2.2.2    Standard Treatment Modalities for Carotid Artery Stenosis

2.2.2.1     Carotid Endarterectomy

2.2.3    Carotid Stenting Technique

2.2.4    Carotid Stents in U.S. Trials and Under Development

2.2.5    U.S. Market for Carotid Artery Stenting Products

2.3   Iliac Artery Stenting Systems

2.3.1    Treatment of  Iliac Artery Occlusive Disease

2.3.1.1     Iliac Artery Angioplasty and Stenting

2.3.2    Iliac Stents in the Market and Under Development

2.3.3    U.S. Market for Iliac Stents

2.3.3.1     Competitive Analysis

2.4   Superficial Femoral & Popliteal Artery Stenting

2.4.1    Treatment of Femoropopliteal Arterial Occlusions

2.4.1.1     Femoropopliteal Angioplasty and Stenting

2.4.2    Femoropopliteal Stents in the Market and Under Development

2.4.3    U.S. Market for Femoropopliteal Stents

2.4.3.1     Competitive Analysis

2.5   Renal Artery Stenting

2.5.1    Treatment of Occlusive Renal Artery Disease

2.5.1.1     Renal Artery Angioplasty and Stenting

2.5.2    Renal Artery Stents in the U.S. Market and Under Development

2.5.3    U.S. Market for Renal Artery Stents

2.5.3.1     Competitive Analysis

2.6   Transjugular Intrahepatic Portosystemic Shunt Systems

2.6.1    Treatment of Portal Hypertension and Variceal Bleeding

2.6.1.1     Transjugular Intrahepatic Portosystemic Shunt Placement Procedure

2.6.2    TIPS Systems in the U.S. Market

2.6.3    U.S. Market for TIPS Systems

2.6.3.1     Competitive Analysis

Section 3:     Non-Vascular Stenting Products

3.1   Biliary Stenting Systems

3.1.1    Treatment of Bile Duct Obstructions

3.1.1.1     Stent-Based Bile Duct Recanalization

3.1.2    Biliary Stents in the U.S. Market

3.1.3    U.S. Biliary Stent Market

3.1.3.1     Competitive Analysis

3.2   GI Tract Stenting Systems

3.2.1    Stent-Based Management of Lower GI Tract Obstructions

3.2.2    Colorectal Stents in the U.S. Market and Under Development

3.2.3    U.S. Market for Colorectal Stents

3.2.3.1     Competitive Analysis

3.2.4    Stent-Based Management of Upper GI Tract Obstructions

3.2.5    Esophageal Stents in the U.S. Market and Under Development

3.2.6    U.S. Market for Esophageal Stents

3.2.6.1     Competitive Analysis

3.3   Pulmonary (Upper Airway) Stenting Systems

3.3.1    Stent-Based Management of Upper Airway Obstructions

3.3.2    Laryngeal and Tracheobronchial Stents in the U.S. Market and Under Development

3.3.3    U.S. Market for Laryngeal and Tracheobronchial Stents

3.3.3.1     Competitive Analysis

3.4   Urological Stenting Systems

3.4.1    Stent-Based Management of Upper Urinary Tract Obstructions

3.4.1.1     Ureteral Stents in the U.S. Market and Under Development

3.4.1.2     U.S. Market for Ureteral Stents

3.4.1.2.1      Competitive Analysis

3.4.2    Stent-Based Management of Lower Urinary Tract Obstructions

3.4.2.1     Urethral Stents in the U.S. Market and Under Development

3.4.3    U.S. Market for Urethral Stents

Section 4:     Company Profiles

4.1   American Cytoscope Makers, Inc. (ACMI, formerly Circon)

4.2   American Medical Systems

4.3   AngioDynamics (E-Z-EM)

4.4   C.R. Bard

4.5   Boston Scientific Corporation

4.6   Bryan Corporation

4.7   Cook Group

4.8   Cordis (Johnson & Johnson)

4.9   Guidant Corporation

4.10   Hood Laboratories

4.11   IntraTherapeutics (EV3, Inc.)

4.12   Medtronic

4.13   Vascular Architects, Inc.

4.14   W.L. Gore & Associates

Appendix:    Company Listing

 

 

LIST OF EXHIBITS

 

Exhibit ES-1: U.S. Incidence of Chronic Medical Conditions and Circulatory Disorders Targeted by Peripheral Vascular and Non-Vascular Stenting (#000)

Exhibit ES-2: Non-Coronary Vascular and Non-Vascular Stenting Procedure Forecast, 2002-2007 (#000)

Exhibit ES-3: U.S. Markets for Non-Coronary Vascular and Non-Vascular Stents, 2002-2007 ($mil)

Exhibit ES-4: Peripheral Vascular and Neurovascular Stenting Procedure Forecast, 2002-2007 (#000)

Exhibit ES-5: U.S. Markets for Peripheral and Neurovascular Stenting Products, 2002-2007 ($mil)

Exhibit ES-6: Non-Vascular Stenting Procedure Forecast, 2002-2007 (#000)

Exhibit ES-7: Non-Vascular Stenting Product Market Forecast, 2002-2007 ($mil)

Exhibit 1-1: Selected Anti-Restenosis Drugs and Delivery Techniques Employed in Commercially Available and Investigational DES Systems

Exhibit 1-2: Selected Bioabsorbable Stenting Technologies In Trials And Under Development

Exhibit 1-3: Plausible Impact of Newly Emerging Competing Peripheral Revascularization Technologies on Utilization of Stenting in Interventional Radiology Practices

Exhibit 2-1: Projected Growth of Peripheral Vascular Stenting Procedures, 2002-2007 (#000)

Exhibit 2-2: Projected Growth of Peripheral Vascular Stenting System Market, 2002-2007 ($mil))

Exhibit 2-3: AAA Endografts in the Market and Under Development

Exhibit 2-4: U.S. Market for AAA Endografts, 2002-2007

Exhibit 2-5: Market Shares of the U.S. Suppliers of AAA Endografts, 2002

Exhibit 2-6: Carotid Stents in Trials and Under Development

Exhibit 2-7: U.S. Market for Carotid Artery Stenting Systems, 2002-2007

Exhibit 2-8: Iliac Stenting Systems in the Market and Under Development

Exhibit 2-9: U.S. Market for Iliac Stents, 2002-2007

Exhibit 2-10: Market Shares of the U.S. Suppliers of Iliac Stents, 2002

Exhibit 2-11: Superficial Femoral and Popliteal Artery Stents in the Market and Under Development

Exhibit 2-12: U.S. Market for Femoropopliteal Stenting Systems, 2002-2007

Exhibit 2-13: Market Shares of the U.S. Suppliers of Femoropopliteal Stents, 2002

Exhibit 2-14: Renal Artery Stents in the Market and Under Development

Exhibit 2-15: U.S. Market for Renal Artery Stenting Systems, 2002-2007

Exhibit 2-16: Market Shares of the U.S. Suppliers of Renal Artery

Exhibit 2-17: Transjugular Intrahepatic Portosystemic Shunts in the Market and Under Development

Exhibit 2-18: U.S. Market for Transjugular Intrahepatic Portosystemic Shunts, 2002-2007

Exhibit 2-19: Market Shares of the U.S. Suppliers of TIPS Systems, 2002

Exhibit 3-1: Non-Vascular Stenting Procedure Forecast, 2002-2007 (#000)

Exhibit 3-2: U.S. Market for Non-Vascular Stenting Products, 2002-2007 ($ mil)

Exhibit 3-3: Biliary Stenting Systems in the U.S. Market

Exhibit 3-4: U.S. Market for Biliary Stenting Systems, 2002-2007

Exhibit 3-5: Market Shares of the U.S. Suppliers of Biliary Stents*, 2002

Exhibit 3-6: Colorectal Stenting Systems in the U.S. Market

Exhibit 3-7: U.S. Colorectal Stenting Systems Market, 2002-2007

Exhibit 3-8: Market Shares of the U.S. Suppliers of Colorectal Stents, 2002

Exhibit 3-9: Esophageal Stents in the U.S. Market

Exhibit 3-10: U.S. Esophageal Stent Market, 2002-2007

Exhibit 3-11: Market Shares of the U.S. Suppliers of Esophageal Stents, 2002

Exhibit 3-12: Selected Stenting Systems for Management of Upper Airway Obstructions

Exhibit 3-13: U.S. Upper Airway Stent Market, 2002-2007

Exhibit 3-14: Market Shares of the U.S. Suppliers of Upper Airway Stenting Systems, 2002

Exhibit 3-15: Ureteral Stenting Systems in the U.S. Market

Exhibit 3-16: U.S. Ureteral Stent Market Forecast, 2002-2007

Exhibit 3-17: Market Shares of the U.S. Suppliers of Ureteral Stents, 2002

Exhibit 3-18: Urethral Stents in the U.S. Market and Under Development

Exhibit 3-19: U.S. Urethral Stent Market Forecast, 2002-2007


 

Technologies, Products and U.S. Markets in Peripheral Stents

Report #C275, July 2003

Price:  $1,450 (delivered in PDF)

 

Order online

 

Methodology.
MedMarket Diligence Reports are produced through primary and secondary research. Data is gathered from published sources on products and technologies on the market and under development.  Clinicians and industry representatives are interviewed for their knowledge and insights on product development, market development, clinical practice and trends associated with the evolving use of technologies. Secondary data is used to corroborate and support assessments and projections.  Reports are written and researched by industry insiders, whose familiarity with the companies, industry dynamics and other marketplace specifics facilitate the research process and ensure high quality and thorough reports.

 

 Contact: Patrick Driscoll, (949) 859-3401.

Copyright 2006 MedMarket Diligence, LLC. All rights reserved.
Revised: 02/16/11

Or call
+1.949.891.1753

+1.949.859.3401
+1.949.837.4558 fax
1.866.820.1357 toll-free (US)

 

 
Follow us on Twitter
Follow medmarket

MedMarket Diligence Reports

 

White Paper
High Growth
Medical Technologies

October 2009

 

 

Medtech Startups
Online database of recent medtech startups

 

 

Contact Us